OverweightNCT02320110
Correlation of Irisin and Adipokine Levels With Body Mass Index and Risk Factors for Metabolic Syndrome in Hispanic Children
An observational study of Overweight and Obesity, run by Instituto Tecnologico y de Estudios Superiores de Monterey at 1 site in Mexico.
Trial summary
Childhood obesity is one of the most serious global public health challenges of the 21st century (Daniels et al., 2009). Mexico has the highest prevalence of obesity, (Secretaría de Salud, 2009); 34.4% of children and 35% of adolescents are overweight or obese (ENSANUT 2012). Read more about this study
- Who is it for?
- Ages 6 to 12 years
- Conditions the study is for
- Overweight, Obesity, Thinness
- How many people
- 40 participants
- Where
- 1 siteMexico
- Study dates
- Sep 2014to Nov 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 12 years
- All sexes
- No healthy volunteers
- Child
Study population: Obese, overweight, normal weight and underweight Hispanic, school-aged children from eight public schools representative of Monterrey, the second largest city in México.
Who may be able to join
- Attendance to school from first to sixth grade
- Ages 6-12 years
- Hispanic origin
- Both parents Hispanic
- 12 hour overnight fast
- Signed consent from both parents/care givers and active assent from children
Who cannot join
- Disapproval by the children's physician due to any at-risk medical condition known by the parents
- Use of drugs for high blood pressure, hyperglycemia, or dyslipidemia
Trial locations and contacts
1 site in 1 country.
Mexico1 site
Clinical Nutrition and Obesity Research Center. School of Medicine, TEC Salud, Tecnológico de Monterrey
Monterrey, Nuevo León, 64710
About this study
Official title: Correlation of Circulating Irisin and Adipokine Levels Across a Broad Spectrum of Body Mass Index Ranging From Undernourished to Obese and With Insulin Resistance and Risk Factors for the Metabolic Syndrome in Hispanic Children
Childhood obesity is one of the most serious global public health challenges of the 21st century (Daniels et al., 2009). Mexico has the highest prevalence of obesity, (Secretaría de Salud, 2009); 34.4% of children and 35% of adolescents are overweight or obese (ENSANUT 2012). Obesity has major health consequences for children and adolescents; On the other hand, undernutrition as well has important deleterious consequences on children's health.
Anything that disrupts energy balance may cause individuals to be underweight, overweight or obese. Fat has been considered an endocrine organ for some time (Elizondo, 2011). Recently, skeletal muscle has been shown to function as a peripheral endocrine organ by releasing myokines, (Pedersen, 2012). Most recently, a new identified hormone secreted by muscle tissue in mouse, irisin, has been discovered. Irisin acts on white adipose cells in culture and in vivo to stimulate UCP1 expression and a broad program of brown-fat-like development. Irisin was induced with exercise in mice and humans which caused an increase in energy expenditure in mice with no changes in movement or food intake (Boström et al., 2012).
Read more
Irisin was thus, promptly hypothesized as a hormone influencing body weight, obesity and type 2 diabetes mellitus, among other conditions (Sanchis-Gomar et al., 2012). Some studies have indicated that circulating levels of irisin in humans correlate positively with anthropometric parameters such as BMI, fat mass, fat free mass, and are higher in obese patients compared to lean ones (Stengel et al., 2013; Huh et al., 2012; Roca-Rivada et al., 2013; Crujeiras et al., 2014; Pardo, 2014). Studies have shown an association between irisin levels, insulin resistance and the metabolic syndrome (Park et al., 2013; de la Iglesia et al., 2014; Crujeiras et al., 2014; Pardo et al., 2014). However, some others have found a negative correlation with anthropometric parameters, finding lower irisin levels in obese patients (Moreno-Navarrete et al., 2013). Noteworthy, all these studies have been performed in adults. To date, there are only two studies evaluating irisin levels in children. One found that a 1-year long lifestyle intervention program was associated with an elevation in irisin levels in obese children, although no correlation was found between irisin levels and anthropometric markers (Blüher et al., 2014). The other study investigated normal weight Saudi children and found correlations between circulating irisin and glucose and HDLc, but a negative association with insulin resistance (Al-Daghri et al, 2014).
Besides, associations between irisin levels and adiponectin, leptin and resistin in the set of obesity have been explored, the three of them are implicated in the physiopatology of obesity.
As there are still conflicting data regarding the association of irisin with anthropometric parameters, obesity and the metabolic syndrome, as well as its 'association with other adiponectines, and most important, there is scarce data of these associations in children, the objective of this study will be to correlate the circulating irisin and adipokines levels across a broad spectrum of body mass index ranging from undernourished to obese as well as with insulin resistance and risk factors for the metabolic syndrome in Hispanic children.
The sample size with statistical power for this study yielded a sample of 40 children. Frozen stored plasma (-80°C) will be taken from a previous study performed in children which has been published (Elizondo-Montemayor et al., 2014). The samples will be divided into five groups, 8 per group, according to the CDC and American Academy of Pediatrics body mass index percentile classification: 1.) underweight = <3 percentile; 2.) normal weight = >3 - < 85 percentile; 3.) Overweight = >85 - < 95 percentile, and 4.) obese = > 95 percentile. The fifth group will correspond to children with known metabolic syndrome according to the classification specified by Cooks et al (2008). Anthropometric measurements will include BMI, percentile BMI, waist circumference, % body fat, fat mass, fat free mass, and triceps skin fold. Biochemical measurements will include glucose, total cholesterol, low-density cholesterol (LDL), high-density cholesterol (HDL-c) and triglycerides. Clinical measurements will include blood pressure, physical activity records and dietary habits. All biochemical, anthropometric and clinical measurements were previously performed in a former published study (Elizondo-Montemayor et al., 2014).
Irisin, adiponectin and leptin will be measured in plasma media using commercial ELISA kits.
Read the detailed description
Background Childhood obesity is one of the most serious global public health challenges of the 21st century (Daniels et al., 2009). Mexico has the highest prevalence of obesity, worldwide; 34.4% of children and 35% of adolescents are overweight or obese (ENSANUT 2012). Among other complications, overweight and obese children are predisposed to develop dyslipidemias, hypertension, the metabolic syndrome (MetS) and non-alcoholic fatty liver disease at a younger age, as well as to become obese as adults (Daniels et al., 2009; Elizondo-Montemayor et al., 2010). On the other hand, undernutrition in children conveys to very detrimental health effects such as stunting, puberty retardation, motor retardation (Roulet et al., 2005), osteoporosis and fractures (Saunders et al., 2011), immunologic deficit, and altered function of every organ and system, such as the heart, lungs, kidneys, gastrointestinal tract and the nervous system, among others (Lecours et al, 2001; Saunders et al., 2011).
A balance between energy intake and energy expenditure is required to sustain a normal body weight. Anything that disrupts this balance may cause individuals to be underweight, overweight or obese. Diverse signals, central and peripheric participate in the regulation of energy balance. Fat has been considered an endocrine organ due to the many peptides and hormones that it secrets that act upon peripheral and central tissues, and their contribution to insulin resistance or sensitivity and body weight regulation among other functions (Elizondo, 2011). Recently, skeletal muscle has been shown to function as a peripheral endocrine organ by releasing myokines, peptide signals, which are implicated in the regulation of metabolic pathways (Pedersen and Febbraio, 2012). Most recently, a new identified hormone secreted by muscle tissue in mouse, irisin, has been discovered. Irisin acts on white adipose cells in culture and in vivo to stimulate UCP1 expression and a broad program of brown-fat-like development. In mouse, PGC1alfa expression in muscle stimulates increase in expression of FNDC5, a membrane protein that is cleaved and secreted as this novel hormone, irisin. Irisin is induced with exercise in mice and humans, and medley increased irisin levels in blood cause an increase in energy expenditure in mice with no changes in movement or food intake (Boström et al., 2012).
Irisin was thus, promptly hypothesized as a hormone influencing body weight, obesity and type 2 diabetes mellitus, among other conditions (Sanchis-Gomar et al., 2012). Some studies have indicated that circulating levels of irisin in humans correlate positively with anthropometric parameters such as BMI, fat mass, fat free mass, and are higher as these parameters increase, this is, irisin levels are higher in obese patients compared to lean ones (Stengel et al., 2013; Huh et al., 2012; Roca-Rivada et al., 2013; Crujeiras et al., 2014; Pardo et al., 2014). Studies have shown an association between irisin levels, insulin resistance and the metabolic syndrome (Park et al., 2013; de la Iglesia et al., 2014; Crujeiras et al., 2014; Pardo et al., 2014). However, some others have found a negative correlation with anthropometric parameters, finding lower irisin levels in obese patients (Moreno-Navarrete et al., 2013). Noteworthy, all these studies have been performed in adults in different circumstances or diseased states. To date, there are only two studies evaluating irisin levels in children. One found that a 1-year long lifestyle intervention program was associated with improvement in anthropometric and metabolic parameters and led to an elevation in irisin levels in obese children, although no correlation was found between irisin levels and anthropometric markers (Blüher et al., 2014). The other study investigated normal weight Saudi children and found correlations between circulating irisin and glucose and HDLc, but a negative association with insulin resistance (Al-Daghri et al., 2014).
Besides, associations between irisin levels and adiponectin, leptin and resistin in the set of obesity have been explored. Leptin plays a pivotal role in regulating energy homeostasis, food intake and many neuroendocrine functions, specially triggering puberty in children. Leptin is increased in obese patients, associated with a leptin-resistant state (Blüher and Mantzoros, 2009). Adiponectin is an insulin sensitizing hormone; obese patients have lower levels than normal-weight ones. Circulating adiponectin levels are low in central obesity (Dalamaga et al., 2012), and this low level has been associated with the metabolic syndrome across all ages (Siitonen et al., 2011). Resistin has been associated with insulin resistance, and recently as a proinflamatory adipocytokine (McTernan et al., 2006). Some studies have found a negative correlation between irisin and adiponectin levels (Park et al., 2013), while other have found no association either with leptin or adiponectin (Blüher et al., 2014) here are still conflicting data regarding the association of irisin with anthropometric parameters, obesity and the metabolic syndrome, as well as its 'association with other adipokines, and most important, there is scarce data of these associations in children, the objective of this study will be to correlate the circulating irisin and adipokines levels across a broad spectrum of body mass index ranging from undernourished to obese as well as with insulin resistance and risk factors for the metabolic syndrome in Hispanic children.
There is still conflicting data regarding the association of irisin with anthropometric parameters, obesity and the metabolic syndrome, as well as its 'association with other adipokines, and most important, there is scarce data of these associations in children. Therefore, the objective of this study will be to correlate the circulating irisin and adipokines levels across a broad spectrum of body mass index ranging from undernourished to obese as well as with insulin resistance and risk factors for the metabolic syndrome in Hispanic children.
Study Population The population was previously described. (Elizondo-Montemayor et al., 2014) An open invitation was made to school-aged children from eight public schools representative of all geographical areas of Monterrey, the second largest city in México. Children that accepted the invitation were randomly selected and screened according to BMI percentiles. The sample size is 40 children. The population will be divided into five groups, 8 per group. Four of the groups will be divided according to the CDC body mass index percentiles: 1.) underweight = <3percentile; 2.) normal weight = >3 - < 85 percentile; 3.) Overweight = >85 - < 95 percentile, and 4.) obese = > 95 percentile. The fifth group will correspond to children with known metabolic syndrome.
Signed consent was obtained from both parents/care givers and children. Approvals by the Ethics and Research Committees of the School of Medicine Tecnológico de Monterrey and by the State Health Secretariat, as well as by the Education Authorities were obtained. Participants did not receive gratification during the study.
Anthropometric and Clinical Evaluation Anthropometric measurements were performed in all participants at each school. Height was determined to the nearest 0.5 cm (portable Seca® stadiometer, North America) and weight to the nearest 0.1 kg while children wore light clothing, no socks or shoes (TANITA TBF 300® scale, Arlington, Illinois). Percentage of body fat (%BF) was measured by bioimpedance (same TANITA scale). WC was measured to the nearest 0.1 cm at the level of the umbilicus with a flexible fiberglass tape while the subjects were standing, after gently exhaling, and with no clothing on the area. Tricipital skin fold (TSF) was measured using a Lange skinfold caliper. BMI was calculated by weight-kilograms divided by the square of height-meters. Fat mass and fat free mass were calculated according to the specific predetermined formulas. Measurements were performed at the same time each day by the same three trained registered dietitians (RD) in all children to control the inter-observer variability. Blood pressure was measured by the same physician, using an aneroid sphygmomanometer (Welch-Allyn®) following the American Heart Association (AHA) technique; two measurements were obtained while participants were calmed and seated.
Laboratory Assessment Blood samples were taken after a 12-hour overnight fast and were kept at 2 to 8°C and centrifuged within the first 3 hours. Serum total cholesterol (TC), HDL-C, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and glucose were measured by reflective photometry (Beer-Lambert's law) using an automated analyzer (Architect c8000; Abbott Laboratories, Abbott Park, IL), with an intra- and inter-assay coefficient variation below 4.7%. Plasma samples were then stored at -80°C. Irisin, adiponectin, insulin and leptin will be measured in plasma media using commercial ELISA kits. The assays will be conducted in 96-well microplates according to the manufacturer's instructions (Irisin, adiponectin, insulin and leptin ELISA kit; Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA). Absorbance from each sample will measured in duplicate using a spectrophotometric microplate reader at wavelength of 450 nm (BioTek Instruments, Winooski, VT, USA).
Statistical Methods MINITAB version 16 (Minitab Inc., State College, PA, USA) will be used to analyze the differences between anthropometric and biochemical parameters and irisin levels; Microsoft Excel 2007 (Microsoft Corp., Redmond, WA, USA) will be used to incorporate the input of data. The results will be expressed as mean ± standard deviation (s.d.), as absolute number or as percentage (%) and their corresponding 95% confidence intervals (CI). Comparisons between groups for the dependent variables will be made using paired Student´s t-test for means and McNemar test for proportions. For independent variables, the normality will be revised both, graphically and by the Shapiro-Wilk test, and subsequently, the comparisons between groups will be determined using z-test. To assess the association between anthropometric, clinical and biochemical variables and irisin levels, a simple linear regression will be used. The mean comparisons between gender groups will be determined using t-test for independent samples. All tests will be interpreted based on two-tailed hypothesis. The significance level will be set at 0.05 in all cases.
- Conditions
- Overweight, Obesity, Thinness
- Keywords
- Irisin, Adiponectin, Leptin, Insulin resistance, Body Mass Index, Obesity, Metabolic Syndrome, Lipid Profile, Diabetes Mellitus
- Medical subject headings
- Overweight, Obesity, Thinness, Insulin Resistance, Metabolic Syndrome, Diabetes Mellitus
What is being measured
The primary outcome is the main question the study is designed to answer.
Irisin levels identification in Hispanic children
Measured: 3 months
Correlation of irisin levels with body mass index percentiles in Hispanic children
Correlation of irisin plasma levels with body mass index percentiles
Measured: 3 months
Correlation of irisin leves with risk factors for metabolic syndrome in Hispanic children
The risk factors include: waist circumference, % body fat, triceps skin fold, fat mass, fat free mass and blood presurre measurements, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides and glucose serum levels
Measured: 3 months
Secondary outcomes (1)
Irisin plasma levels and adiponectin, leptin, insulin and resistin.
correlation of irisin plasma levels adiponectin, leptin, resistin and insluin
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Dec 2014 (estimated)
- Study startSep 2014
- Primary completionNov 2014
- Study completionNov 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (25)Papers the sponsor has linked to this study.
- Other trials for OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto Tecnologico y de Estudios Superiores de Monterey
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Leticia Elizondo-Montemayor, Instituto Tecnologico y de Estudios Superiores de Monterey
- Investigators
- Leticia Elizondo-Montemayor, MD, Principal investigator, Clinical Nutrition and Obesity Research Center. TEC Salud, School of Medicine Tecnológico de Monterrey
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02320110
- Sponsor's protocol ID
- DIETARYHABITS2014-CINCO
- Status last verified
- Dec 2014
- First submitted
- 2 Dec 2014
- Last updated
- 19 Dec 2014
- Results posted
- No
Publications
Daniels SR, Jacobson MS, McCrindle BW, Eckel RH, Sanner BM. American Heart Association Childhood Obesity Research Summit Report. Circulation. 2009 Apr 21;119(15):e489-517. doi: 10.1161/CIRCULATIONAHA.109.192216. Epub 2009 Mar 30. No abstract available.
PubMed 19332458Elizondo-Montemayor L, Serrano-Gonzalez M, Ugalde-Casas PA, Cuello-Garcia C, Borbolla-Escoboza JR. Metabolic syndrome risk factors among a sample of overweight and obese Mexican children. J Clin Hypertens (Greenwich). 2010 May;12(5):380-7. doi: 10.1111/j.1751-7176.2010.00263.x.
PubMed 20546382Roulet M, Cheseaux M, Coti P. Consequences of disease-related malnutrition in children and adolescents: Mortality, morbidity and costs. Arch Pediatr 12(4): 207-213, 2005
Secretaría de Salud. México avanza en la cobertura universal de salud: Felipe Calderón. México Sano. 2009;8:3.
Saunders J, Smith T, Stroud M. Malnutrition and undernutrition. Medicine 39(1): 45-50, 2011
Lecours AR, Mandujano M, Romero G. Ontogeny of brain and cognition: relevance to nutrition research. Nutr Rev. 2001 Aug;59(8 Pt 2):S7-11; discussion S11-2. doi: 10.1111/j.1753-4887.2001.tb05504.x. No abstract available.
PubMed 11519671Elizondo, L. Hernández, C. Zamora, M. (2011). Terapia Nutricia Médica en Ginecología y Obstetricia. México: McGraw-Hill.
Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012 Apr 3;8(8):457-65. doi: 10.1038/nrendo.2012.49.
PubMed 22473333Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hojlund K, Gygi SP, Spiegelman BM. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012 Jan 11;481(7382):463-8. doi: 10.1038/nature10777.
PubMed 22237023Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, Garcia-Gimenez JL. Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes. 2012 Sep;4(3):196. doi: 10.1111/j.1753-0407.2012.00194.x. No abstract available.
PubMed 22372821Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity--correlation with body mass index. Peptides. 2013 Jan;39:125-30. doi: 10.1016/j.peptides.2012.11.014. Epub 2012 Dec 3.
PubMed 23219488Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012 Dec;61(12):1725-38. doi: 10.1016/j.metabol.2012.09.002. Epub 2012 Sep 25.
PubMed 23018146Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Belen Crujeiras A, Seoane LM, Casanueva FF, Pardo M. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One. 2013 Apr 11;8(4):e60563. doi: 10.1371/journal.pone.0060563. Print 2013.
PubMed 23593248Crujeiras AB, Zulet MA, Lopez-Legarrea P, de la Iglesia R, Pardo M, Carreira MC, Martinez JA, Casanueva FF. Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism. 2014 Apr;63(4):520-31. doi: 10.1016/j.metabol.2013.12.007. Epub 2013 Dec 18.
PubMed 24439241Pardo M, Crujeiras AB, Amil M, Aguera Z, Jimenez-Murcia S, Banos R, Botella C, de la Torre R, Estivill X, Fagundo AB, Fernandez-Real JM, Fernandez-Garcia JC, Fruhbeck G, Gomez-Ambrosi J, Rodriguez R, Tinahones FJ, Fernandez-Aranda F, Casanueva FF. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol. 2014;2014:857270. doi: 10.1155/2014/857270. Epub 2014 Apr 22.
PubMed 24864142
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation of Circulating Irisin and Adipokine Levels Across a Broad Spectrum of Body Mass Index Ranging From Undernourished to Obese and With Insulin Resistance and Risk Factors for the Metabolic Syndrome in Hispanic Children
- ClinicalTrials.gov ID
- NCT02320110
- Acronym / sponsor ID
- DIETARYHABITS2014-CINCO
- Conditions
- Overweight, Obesity, Thinness
- Keywords
- Irisin, Adiponectin, Leptin, Insulin resistance, Body Mass Index, Obesity, Metabolic Syndrome, Lipid Profile
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Instituto Tecnologico y de Estudios Superiores de MontereyUniversity, hospital or other
- Study start
- Sep 2014
- Primary completion
- Nov 2014 (actual)
- Study completion
- Nov 2014 (actual)
- First posted
- 19 Dec 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Childhood obesity is one of the most serious global public health challenges of the 21st century (Daniels et al., 2009). Mexico has the highest prevalence of obesity, (Secretaría de Salud, 2009); 34.4% of children and 35% of adolescents are overweight or obese (ENSANUT 2012). Obesity has major health consequences for children and adolescents; On the other hand, undernutrition as well has important deleterious consequences on children's health.
Anything that disrupts energy balance may cause individuals to be underweight, overweight or obese. Fat has been considered an endocrine organ for some time (Elizondo, 2011). Recently, skeletal muscle has been shown to function as a peripheral endocrine organ by releasing myokines, (Pedersen, 2012). Most recently, a new identified hormone secreted by muscle tissue in mouse, irisin, has been discovered. Irisin acts on white adipose cells in culture and in vivo to stimulate UCP1 expression and a broad program of brown-fat-like development. Irisin was induced with exercise in mice and humans which caused an increase in energy expenditure in mice with no changes in movement or food intake (Boström et al., 2012).
Irisin was thus, promptly hypothesized as a hormone influencing body weight, obesity and type 2 diabetes mellitus, among other conditions (Sanchis-Gomar et al., 2012). Some studies have indicated that circulating levels of irisin in humans correlate positively with anthropometric parameters such as BMI, fat mass, fat free mass, and are higher in obese patients compared to lean ones (Stengel et al., 2013; Huh et al., 2012; Roca-Rivada et al., 2013; Crujeiras et al., 2014; Pardo, 2014). Studies have shown an association between irisin levels, insulin resistance and the metabolic syndrome (Park et al., 2013; de la Iglesia et al., 2014; Crujeiras et al., 2014; Pardo et al., 2014). However, some others have found a negative correlation with anthropometric parameters, finding lower irisin levels in obese patients (Moreno-Navarrete et al., 2013). Noteworthy, all these studies have been performed in adults. To date, there are only two studies evaluating irisin levels in children. One found that a 1-year long lifestyle intervention program was associated with an elevation in irisin levels in obese children, although no correlation was found between irisin levels and anthropometric markers (Blüher et al., 2014). The other study investigated normal weight Saudi children and found correlations between circulating irisin and glucose and HDLc, but a negative association with insulin resistance (Al-Daghri et al, 2014).
Besides, associations between irisin levels and adiponectin, leptin and resistin in the set of obesity have been explored, the three of them are implicated in the physiopatology of obesity.
As there are still conflicting data regarding the association of irisin with anthropometric parameters, obesity and the metabolic syndrome, as well as its 'association with other adiponectines, and most important, there is scarce data of these associations in children, the objective of this study will be to correlate the circulating irisin and adipokines levels across a broad spectrum of body mass index ranging from undernourished to obese as well as with insulin resistance and risk factors for the metabolic syndrome in Hispanic children.
The sample size with statistical power for this study yielded a sample of 40 children. Frozen stored plasma (-80°C) will be taken from a previous study performed in children which has been published (Elizondo-Montemayor et al., 2014). The samples will be divided into five groups, 8 per group, according to the CDC and American Academy of Pediatrics body mass index percentile classification: 1.) underweight = <3 percentile; 2.) normal weight = >3 - < 85 percentile; 3.) Overweight = >85 - < 95 percentile, and 4.) obese = > 95 percentile. The fifth group will correspond to children with known metabolic syndrome according to the classification specified by Cooks et al (2008). Anthropometric measurements will include BMI, percentile BMI, waist circumference, % body fat, fat mass, fat free mass, and triceps skin fold. Biochemical measurements will include glucose, total cholesterol, low-density cholesterol (LDL), high-density cholesterol (HDL-c) and triglycerides. Clinical measurements will include blood pressure, physical activity records and dietary habits. All biochemical, anthropometric and clinical measurements were previously performed in a former published study (Elizondo-Montemayor et al., 2014).
Irisin, adiponectin and leptin will be measured in plasma media using commercial ELISA kits.
Detailed description
Background Childhood obesity is one of the most serious global public health challenges of the 21st century (Daniels et al., 2009). Mexico has the highest prevalence of obesity, worldwide; 34.4% of children and 35% of adolescents are overweight or obese (ENSANUT 2012). Among other complications, overweight and obese children are predisposed to develop dyslipidemias, hypertension, the metabolic syndrome (MetS) and non-alcoholic fatty liver disease at a younger age, as well as to become obese as adults (Daniels et al., 2009; Elizondo-Montemayor et al., 2010). On the other hand, undernutrition in children conveys to very detrimental health effects such as stunting, puberty retardation, motor retardation (Roulet et al., 2005), osteoporosis and fractures (Saunders et al., 2011), immunologic deficit, and altered function of every organ and system, such as the heart, lungs, kidneys, gastrointestinal tract and the nervous system, among others (Lecours et al, 2001; Saunders et al., 2011).
A balance between energy intake and energy expenditure is required to sustain a normal body weight. Anything that disrupts this balance may cause individuals to be underweight, overweight or obese. Diverse signals, central and peripheric participate in the regulation of energy balance. Fat has been considered an endocrine organ due to the many peptides and hormones that it secrets that act upon peripheral and central tissues, and their contribution to insulin resistance or sensitivity and body weight regulation among other functions (Elizondo, 2011). Recently, skeletal muscle has been shown to function as a peripheral endocrine organ by releasing myokines, peptide signals, which are implicated in the regulation of metabolic pathways (Pedersen and Febbraio, 2012). Most recently, a new identified hormone secreted by muscle tissue in mouse, irisin, has been discovered. Irisin acts on white adipose cells in culture and in vivo to stimulate UCP1 expression and a broad program of brown-fat-like development. In mouse, PGC1alfa expression in muscle stimulates increase in expression of FNDC5, a membrane protein that is cleaved and secreted as this novel hormone, irisin. Irisin is induced with exercise in mice and humans, and medley increased irisin levels in blood cause an increase in energy expenditure in mice with no changes in movement or food intake (Boström et al., 2012).
Irisin was thus, promptly hypothesized as a hormone influencing body weight, obesity and type 2 diabetes mellitus, among other conditions (Sanchis-Gomar et al., 2012). Some studies have indicated that circulating levels of irisin in humans correlate positively with anthropometric parameters such as BMI, fat mass, fat free mass, and are higher as these parameters increase, this is, irisin levels are higher in obese patients compared to lean ones (Stengel et al., 2013; Huh et al., 2012; Roca-Rivada et al., 2013; Crujeiras et al., 2014; Pardo et al., 2014). Studies have shown an association between irisin levels, insulin resistance and the metabolic syndrome (Park et al., 2013; de la Iglesia et al., 2014; Crujeiras et al., 2014; Pardo et al., 2014). However, some others have found a negative correlation with anthropometric parameters, finding lower irisin levels in obese patients (Moreno-Navarrete et al., 2013). Noteworthy, all these studies have been performed in adults in different circumstances or diseased states. To date, there are only two studies evaluating irisin levels in children. One found that a 1-year long lifestyle intervention program was associated with improvement in anthropometric and metabolic parameters and led to an elevation in irisin levels in obese children, although no correlation was found between irisin levels and anthropometric markers (Blüher et al., 2014). The other study investigated normal weight Saudi children and found correlations between circulating irisin and glucose and HDLc, but a negative association with insulin resistance (Al-Daghri et al., 2014).
Besides, associations between irisin levels and adiponectin, leptin and resistin in the set of obesity have been explored. Leptin plays a pivotal role in regulating energy homeostasis, food intake and many neuroendocrine functions, specially triggering puberty in children. Leptin is increased in obese patients, associated with a leptin-resistant state (Blüher and Mantzoros, 2009). Adiponectin is an insulin sensitizing hormone; obese patients have lower levels than normal-weight ones. Circulating adiponectin levels are low in central obesity (Dalamaga et al., 2012), and this low level has been associated with the metabolic syndrome across all ages (Siitonen et al., 2011). Resistin has been associated with insulin resistance, and recently as a proinflamatory adipocytokine (McTernan et al., 2006). Some studies have found a negative correlation between irisin and adiponectin levels (Park et al., 2013), while other have found no association either with leptin or adiponectin (Blüher et al., 2014) here are still conflicting data regarding the association of irisin with anthropometric parameters, obesity and the metabolic syndrome, as well as its 'association with other adipokines, and most important, there is scarce data of these associations in children, the objective of this study will be to correlate the circulating irisin and adipokines levels across a broad spectrum of body mass index ranging from undernourished to obese as well as with insulin resistance and risk factors for the metabolic syndrome in Hispanic children.
There is still conflicting data regarding the association of irisin with anthropometric parameters, obesity and the metabolic syndrome, as well as its 'association with other adipokines, and most important, there is scarce data of these associations in children. Therefore, the objective of this study will be to correlate the circulating irisin and adipokines levels across a broad spectrum of body mass index ranging from undernourished to obese as well as with insulin resistance and risk factors for the metabolic syndrome in Hispanic children.
Study Population The population was previously described. (Elizondo-Montemayor et al., 2014) An open invitation was made to school-aged children from eight public schools representative of all geographical areas of Monterrey, the second largest city in México. Children that accepted the invitation were randomly selected and screened according to BMI percentiles. The sample size is 40 children. The population will be divided into five groups, 8 per group. Four of the groups will be divided according to the CDC body mass index percentiles: 1.) underweight = <3percentile; 2.) normal weight = >3 - < 85 percentile; 3.) Overweight = >85 - < 95 percentile, and 4.) obese = > 95 percentile. The fifth group will correspond to children with known metabolic syndrome.
Signed consent was obtained from both parents/care givers and children. Approvals by the Ethics and Research Committees of the School of Medicine Tecnológico de Monterrey and by the State Health Secretariat, as well as by the Education Authorities were obtained. Participants did not receive gratification during the study.
Anthropometric and Clinical Evaluation Anthropometric measurements were performed in all participants at each school. Height was determined to the nearest 0.5 cm (portable Seca® stadiometer, North America) and weight to the nearest 0.1 kg while children wore light clothing, no socks or shoes (TANITA TBF 300® scale, Arlington, Illinois). Percentage of body fat (%BF) was measured by bioimpedance (same TANITA scale). WC was measured to the nearest 0.1 cm at the level of the umbilicus with a flexible fiberglass tape while the subjects were standing, after gently exhaling, and with no clothing on the area. Tricipital skin fold (TSF) was measured using a Lange skinfold caliper. BMI was calculated by weight-kilograms divided by the square of height-meters. Fat mass and fat free mass were calculated according to the specific predetermined formulas. Measurements were performed at the same time each day by the same three trained registered dietitians (RD) in all children to control the inter-observer variability. Blood pressure was measured by the same physician, using an aneroid sphygmomanometer (Welch-Allyn®) following the American Heart Association (AHA) technique; two measurements were obtained while participants were calmed and seated.
Laboratory Assessment Blood samples were taken after a 12-hour overnight fast and were kept at 2 to 8°C and centrifuged within the first 3 hours. Serum total cholesterol (TC), HDL-C, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and glucose were measured by reflective photometry (Beer-Lambert's law) using an automated analyzer (Architect c8000; Abbott Laboratories, Abbott Park, IL), with an intra- and inter-assay coefficient variation below 4.7%. Plasma samples were then stored at -80°C. Irisin, adiponectin, insulin and leptin will be measured in plasma media using commercial ELISA kits. The assays will be conducted in 96-well microplates according to the manufacturer's instructions (Irisin, adiponectin, insulin and leptin ELISA kit; Phoenix Pharmaceuticals, Inc., Burlingame, CA, USA). Absorbance from each sample will measured in duplicate using a spectrophotometric microplate reader at wavelength of 450 nm (BioTek Instruments, Winooski, VT, USA).
Statistical Methods MINITAB version 16 (Minitab Inc., State College, PA, USA) will be used to analyze the differences between anthropometric and biochemical parameters and irisin levels; Microsoft Excel 2007 (Microsoft Corp., Redmond, WA, USA) will be used to incorporate the input of data. The results will be expressed as mean ± standard deviation (s.d.), as absolute number or as percentage (%) and their corresponding 95% confidence intervals (CI). Comparisons between groups for the dependent variables will be made using paired Student´s t-test for means and McNemar test for proportions. For independent variables, the normality will be revised both, graphically and by the Shapiro-Wilk test, and subsequently, the comparisons between groups will be determined using z-test. To assess the association between anthropometric, clinical and biochemical variables and irisin levels, a simple linear regression will be used. The mean comparisons between gender groups will be determined using t-test for independent samples. All tests will be interpreted based on two-tailed hypothesis. The significance level will be set at 0.05 in all cases.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 6 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Obese, overweight, normal weight and underweight Hispanic, school-aged children from eight public schools representative of Monterrey, the second largest city in México.
Key inclusion criteria (6 listed)
- Attendance to school from first to sixth grade
- Ages 6-12 years
- Hispanic origin
- Both parents Hispanic
- 12 hour overnight fast
Key exclusion criteria (2 listed)
- Disapproval by the children's physician due to any at-risk medical condition known by the parents
- Use of drugs for high blood pressure, hyperglycemia, or dyslipidemia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Irisin levels identification in Hispanic children
Time frame: 3 months
Correlation of irisin levels with body mass index percentiles in Hispanic children
Time frame: 3 months
Correlation of irisin plasma levels with body mass index percentiles
Correlation of irisin leves with risk factors for metabolic syndrome in Hispanic children
Time frame: 3 months
The risk factors include: waist circumference, % body fat, triceps skin fold, fat mass, fat free mass and blood presurre measurements, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides and glucose serum levels
1 secondary outcome
Irisin plasma levels and adiponectin, leptin, insulin and resistin.
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2014.
- Background: PubMed 19332458Daniels SR, Jacobson MS, McCrindle BW, Eckel RH, Sanner BM. American Heart Association Childhood Obesity Research Summit Report. Circulation. 2009 Apr 21;119(15):e489-517. doi: 10.1161/CIRCULATIONAHA.109.192216. Epub 2009 Mar 30. No abstract available.
- Background: PubMed 20546382Elizondo-Montemayor L, Serrano-Gonzalez M, Ugalde-Casas PA, Cuello-Garcia C, Borbolla-Escoboza JR. Metabolic syndrome risk factors among a sample of overweight and obese Mexican children. J Clin Hypertens (Greenwich). 2010 May;12(5):380-7. doi: 10.1111/j.1751-7176.2010.00263.x.
- BackgroundRoulet M, Cheseaux M, Coti P. Consequences of disease-related malnutrition in children and adolescents: Mortality, morbidity and costs. Arch Pediatr 12(4): 207-213, 2005
- BackgroundSecretaría de Salud. México avanza en la cobertura universal de salud: Felipe Calderón. México Sano. 2009;8:3.
- BackgroundSaunders J, Smith T, Stroud M. Malnutrition and undernutrition. Medicine 39(1): 45-50, 2011
- Background: PubMed 11519671Lecours AR, Mandujano M, Romero G. Ontogeny of brain and cognition: relevance to nutrition research. Nutr Rev. 2001 Aug;59(8 Pt 2):S7-11; discussion S11-2. doi: 10.1111/j.1753-4887.2001.tb05504.x. No abstract available.
- BackgroundElizondo, L. Hernández, C. Zamora, M. (2011). Terapia Nutricia Médica en Ginecología y Obstetricia. México: McGraw-Hill.
- Background: PubMed 22473333Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012 Apr 3;8(8):457-65. doi: 10.1038/nrendo.2012.49.
- Background: PubMed 22237023Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hojlund K, Gygi SP, Spiegelman BM. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012 Jan 11;481(7382):463-8. doi: 10.1038/nature10777.
- Background: PubMed 22372821Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, Garcia-Gimenez JL. Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes. 2012 Sep;4(3):196. doi: 10.1111/j.1753-0407.2012.00194.x. No abstract available.
- Background: PubMed 23219488Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity--correlation with body mass index. Peptides. 2013 Jan;39:125-30. doi: 10.1016/j.peptides.2012.11.014. Epub 2012 Dec 3.
- Background: PubMed 23018146Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012 Dec;61(12):1725-38. doi: 10.1016/j.metabol.2012.09.002. Epub 2012 Sep 25.
Related trials for Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Leticia Elizondo-Montemayor, MD principal investigator
Clinical Nutrition and Obesity Research Center. TEC Salud, School of Medicine Tecnológico de Monterrey
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Overweight and Obesity, run by Instituto Tecnologico y de Estudios Superiores de Monterey at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Irisin levels identification in Hispanic children (time frame: 3 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02320110, which also lists 25 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2014.